Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | FPR2 | P25090 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6393365 | 0.91 | MEN1 (0.64) | POLBMEN1KMT2ALMNAFPR2 | |
| SCHEMBL23417615 | 0.85 | POLB (0.77) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL4023394 | 0.84 | KMT2A (0.79) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL275229 | 0.84 | POLB (0.80) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL12773610 | 0.83 | SMN1; SMN2 (0.75) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL3241452 | 0.83 | RAB9A (0.68) | MEN1KMT2ALMNAFPR2 | |
| SCHEMBL3279814 | 0.83 | TAAR1 (0.74) | KMT2AFPR2ALDH1A1 | |
| SCHEMBL3199349 | 0.82 | POLB (0.78) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL10963023 | 0.82 | POLB (0.78) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL13271651 | 0.82 | HPGD (0.61) | POLBMEN1KMT2ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908931-B2 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | MTNR1A, MTNR1B, PER2 | POLB 2664/4885MEN1 762/4885KMT2A 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.